Assuntos
COVID-19/complicações , COVID-19/terapia , Humanos , SARS-CoV-2 , Síndrome de COVID-19 Pós-AgudaAssuntos
Vacinas contra COVID-19/imunologia , Vacinas contra COVID-19/provisão & distribuição , COVID-19/prevenção & controle , Pneumonia Viral/prevenção & controle , COVID-19/epidemiologia , COVID-19/imunologia , Centers for Disease Control and Prevention, U.S. , Humanos , Pandemias/prevenção & controle , Seleção de Pacientes , Pneumonia Viral/imunologia , Pneumonia Viral/virologia , SARS-CoV-2/imunologia , Estados Unidos/epidemiologia , United States Food and Drug AdministrationAssuntos
Betacoronavirus/imunologia , Congressos como Assunto , Vacinas Virais , Vacinas contra COVID-19 , Ensaios Clínicos como Assunto , Infecções por Coronavirus/prevenção & controle , Medicina Baseada em Evidências , Humanos , SARS-CoV-2 , Estados Unidos , United States Food and Drug AdministrationRESUMO
OBJECTIVES: We investigated potential risk factors for active injection drug use (IDU) in an inner-city cohort of patients infected with hepatitis C virus (HCV). METHODS: We used log-binomial regression to identify factors independently associated with active IDU during the first 3 years of follow-up for the 289 participants who reported ever having injected drugs at baseline. RESULTS: Overall, 142 (49.1%) of the 289 participants reported active IDU at some point during the follow-up period. In a multivariate model, being unemployed (prevalence ratio [PR] = 1.93; 95% confidence interval [CI] = 1.24, 3.03) and hazardous alcohol drinking (PR = 1.67; 95% CI = 1.34, 2.08) were associated with active IDU. Smoking was associated with IDU but this association was not statistically significant. Patients with all 3 of those factors were 3 times as likely to report IDU during follow-up as those with 0 or 1 factor (PR = 3.3; 95% CI = 2.2, 4.9). Neither HIV coinfection nor history of psychiatric disease was independently associated with active IDU. CONCLUSIONS: Optimal treatment of persons with HCV infection will require attention to unemployment, alcohol use, and smoking in conjunction with IDU treatment and prevention.